The efficacy and bio-marker exploration of immune checkpoint inhibitors combined with anti-angiogenic therapy in patients with advanced non-small cell lung cancer after failure of first-line immunotherapy

The efficacy and marker exploration of immune checkpoint inhibitors combined with anti-angiogenic therapy in patients with advanced non-small cell lung cancer after failure of first-line immunotherapy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000035666

Enrollment

Unknown

Registered

2020-08-16

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Case series:Nivolumab combined with anlotinib group

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Male and female patients aged 18-75 with locally advanced or metastatic NSCLC confirmed by pathology are not suitable for radical surgery or radiotherapy, and have no active brain metastases. The patient has previously received ICI treatment for progressive disease.

Exclusion criteria

Exclusion criteria: Exclude subjects with active CNS metastasis or small cell lung cancer (including mixed small cell and non-small cell lung cancer) or cavity central squamous cell carcinoma. Patients with obvious bleeding symptoms. Patients should not receive IO as first-line treatment or have a grade 3 AE while receiving IO treatment.

Design outcomes

Primary

Measure	Time frame
Target lesion;	—

Countries

China

Contacts

Public ContactHua Zhong

Shanghai Chest Hospital

eddiedong8@hotmail.com+86 13818200560

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026